Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study.
Haematologica
; 109(7): 2297-2302, 2024 07 01.
Article
em En
| MEDLINE
| ID: mdl-38497158
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Esplênicas
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Neoplasia Residual
/
Linfoma de Zona Marginal Tipo Células B
/
Cloridrato de Bendamustina
/
Rituximab
Limite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article